The impact of minimal residual disease in acute leukemia is well established in patient outcome.

In this webinar, Cytognos's guest speaker Evan Jensen, will review the evolution of clinical flow cytometry for the evaluation of minimal residual disease (MRD) in acute leukemia over the years. He will also describe the clinical relevance of MRD, current state-of-the-art methodology and the most important technical aspects to perform a good flow cytometry measurement.

40 years of MRD. A review of flow cytometry as an advanced technique for B-ALL monitoring